论文信息 - Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. - 字舞流文

Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies.

M. Perales | C. Turtle | J. Zalevsky | M. Cairo | M. Tagliaferri | A. Cowan | K. Patel | N. Shah | K. Kai | H. Saeed | L. Budde | M. Marcondes | A. Tan | Z. Lee